Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director · President and CEO | June 03, 2026 | June 05, 2026 |
| Avidity Biosciences, Inc.RNA · Entity 11854 | Director | June 11, 2020 | June 12, 2020 |
| Outlook Therapeutics, Inc.ONS · Entity 608 | Director | October 26, 2017 | October 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,721,298 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Purchase · Acquired 250,000 · Balance 1,721,298 F1: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.
Avidity Biosciences, Inc.
Report date June 11, 2020 · Filed June 12, 2020
This filing explicitly reported no securities owned.
Outlook Therapeutics, Inc.
Report date October 26, 2017 · Filed October 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-10-26 | Direct | 15,000 |
Reported balance
After 2017-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-26 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evoke Pharma Inc
Report date December 16, 2025 · Filed December 17, 2025
Section 16 reporting ended · disclosed 2025-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-16 transaction · row 1
1 source rowRow 1 · 2025-12-16 · Other · Disposed 27 · Balance 0 F1: On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.41 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-17 · Disposition to issuer · Disposed 1,218 · Balance 0 F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-17 · Disposition to issuer · Disposed 5,833 · Balance 0 F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price").
F2: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
F-star Therapeutics, Inc.
Report date November 20, 2020 · Filed March 09, 2023
Section 16 reporting ended · disclosed 2023-03-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-08 transaction · row 1
1 source rowRow 1 · 2023-03-08 · Other · Disposed 15,004 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. F2: (Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2031-06-04 | Direct | 0 |
Reported balance
After 2023-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2032-06-17 | Direct | 0 |
Reported balance
After 2023-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2026-07-27 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-20 · Other · Disposed 11,000 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2028-06-17 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2029-07-09 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2021-11-23 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-20 · Other · Disposed 10,964 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023.
F2: (Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)).
F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option.
F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:19 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 250,000 | $1.67 | $418,450.00 |
DisclosureSEC source: 0001193125-26-259637 · ownership.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,721,298 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:17 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantBonus Units · Derivative | 632,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-134631 · ownership.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,318 Underlying: Common Stock · 632,318 shares Expires not disclosed F2 · derivative.exercise_price: The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. F2 · derivative.exercise_date: The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. F2 · derivative.expiration_date: The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:17 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 1,880,510 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001193125-26-134631 · ownership.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,880,510 Underlying: Common Stock · 1,880,510 shares Expires 2036-03-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 16:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,187 | Not disclosed Strike: $3.45 | Not disclosed |
DisclosureSEC source: 0001193125-25-322639 · ownership.xml · derivative · entry 4 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,187 shares Expires not disclosed F2 · price: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. F2 · derivative.exercise_date: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. F2 · derivative.expiration_date: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 16:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,833 | Not disclosed Strike: $4.45 | Not disclosed |
DisclosureSEC source: 0001193125-25-322639 · ownership.xml · derivative · entry 3 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,833 shares Expires not disclosed F2 · price: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. F2 · derivative.exercise_date: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. F2 · derivative.expiration_date: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 16:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,218 | Not disclosed Strike: $5.41 | Not disclosed |
DisclosureSEC source: 0001193125-25-322639 · ownership.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,218 shares Expires not disclosed F2 · price: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. F2 · derivative.exercise_date: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. F2 · derivative.expiration_date: After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 16:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | OtherCommon Stock | 27 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-322639 · ownership.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the "Offer Price"). Read SEC document |
| May 21, 2025 Filed May 22, 2025 17:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0000950170-25-076441 · ownership.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,238 Underlying: Common Stock · 1,187 shares Expires 2035-05-20 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:17 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 809,710 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0000950170-25-034674 · ownership.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 809,710 Underlying: Common Stock · 809,710 shares Expires 2035-03-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2025. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 16:30 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-010532 · ownership.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 5,833 shares Expires 2035-01-27 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option shall vest one-third of the total number of shares each one-year period after the vesting commencement date, so that the option shall be fully vested on the third anniversary of the vesting commencement date, subject to the Holder's continued service to the Company through each such vesting date. Read SEC document |
| May 22, 2024 Filed May 24, 2024 16:53 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 14,625 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0000950170-24-064687 · ownership.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,625 Underlying: Common Stock · 14,625 shares Expires 2034-05-21 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 00:01 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 85,324 | $3.05 | $260,238.20 |
DisclosureSEC source: 0000950170-24-030309 · ownership.xml · nonDerivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,471,298 F1 · kind: These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 97,914 | $3.27 | $320,521.48 |
DisclosureSEC source: 0000950170-24-030309 · ownership.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,556,622 F1 · kind: These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 09, 2024 Filed Mar 13, 2024 00:01 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 1,081,201 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0000950170-24-030309 · ownership.xml · derivative · entry 3 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,081,201 Underlying: Common Stock · 1,081,201 shares Expires 2034-03-08 F4 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionStock Option (right to buy) · Derivative | 48,021 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · derivative · entry 7 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,021 shares Expires 2023-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionStock Option (right to buy) · Derivative | 32,953 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · derivative · entry 6 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,953 shares Expires 2023-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionStock Option (right to buy) · Derivative | 192,084 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · derivative · entry 5 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,084 shares Expires 2023-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Tax withholdingCommon Stock | 73,807 | $7.22 | $532,886.54 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · nonDerivative · entry 4 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,654,536 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the exercise of the stock options. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionCommon Stock | 48,021 | $0.55 | $26,507.59 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · nonDerivative · entry 3 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,728,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionCommon Stock | 32,953 | $0.55 | $18,190.06 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · nonDerivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,680,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:42 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionCommon Stock | 192,084 | $0.55 | $106,030.37 |
DisclosureSEC source: 0000950170-23-047530 · ownership.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,647,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 16:44 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 14,625 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-028784 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,625 Underlying: Common Stock · 14,625 shares Expires 2033-05-09 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $3.41 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 3 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F3 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · kind: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · kind: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · price: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · price: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · derivative.exercise_date: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · derivative.exercise_date: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.88 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-06-04 F3 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · kind: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · kind: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · price: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · price: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · derivative.exercise_date: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · derivative.exercise_date: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherCommon Stock | 15,004 | $7.12 | $106,828.48 |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. F2 · kind: (Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020. F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. F2 · price: (Continued from footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:22 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0000899243-23-006742 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-27 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:22 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 238,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006742 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,455,285 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantBonus Units · Derivative | 604,308 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026346 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,308 Underlying: Common Stock · 604,308 shares Expires not disclosed F1 · derivative.exercise_price: Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. F1 · derivative.exercise_date: Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. F1 · derivative.expiration_date: Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 10:41 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 17,700 | $3.36 | $59,546.34 |
DisclosureSEC source: 0000899243-22-024132 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216,535 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.3591 to $3.3693, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 17:15 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001209191-22-038719 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F1 · shares: These options were granted under the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the Reporting Person's continued service as a director of the company. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 19:07 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 57,750 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001209191-22-026068 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 57,750 shares Expires 2032-04-26 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:44 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantBonus Units · Derivative | 207,758 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0000899243-22-013176 · doc4.xml · derivative · entry 3 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,758 Underlying: Common Stock · 207,758 shares Expires not disclosed F3 · derivative.exercise_price: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52. F3 · derivative.exercise_date: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52. F3 · derivative.expiration_date: The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:44 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0000899243-22-013176 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-03-29 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:44 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013176 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,198,835 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 16:14 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001209191-21-038568 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-04 F1 · shares: These options were granted under the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 4, 2022, subject to the Reporting Person's continued service as a director of the company. Read SEC document |
| May 05, 2021 Filed Jul 23, 2021 18:15 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 57,750 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-21-048017 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 57,750 shares Expires 2031-05-04 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 23:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-21-015837 · doc4.xml · derivative · entry 2 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-04-11 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 23:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 46,619 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-015837 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,835 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $1.60 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 9 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2030-06-23 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $4.62 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 8 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2029-07-09 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 5,500 | Not disclosed Strike: $13.99 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 7 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2028-06-17 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 5,500 | Not disclosed Strike: $14.27 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 6 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2027-06-14 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherWarrant (right to buy) · Derivative | 10,964 | Not disclosed Strike: $10.79 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 5 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,964 shares Expires 2021-11-23 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:17 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 11,000 | Not disclosed Strike: $9.05 | Not disclosed |
DisclosureSEC source: 0000899243-23-007663 · doc4.xml · derivative · entry 4 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-07-27 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 11:17 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | OtherWarrants · Derivative | 2,741 | $0.00 Strike: $43.16 | $0.00 |
DisclosureSEC source: 0000905718-20-001135 · springbank_fm4nov192020.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,741 shares Expires 2021-11-23 F1 · kind: The reported securities were called for redemption by the Issuer at their Black-Scholes value. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 9,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052599 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,016 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 8,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039703 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,781 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-20-038877 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-06-23 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 16:42 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 57,750 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001209191-20-032964 · doc4.xml · derivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 57,750 shares Expires 2030-05-26 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 13,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022073 · doc4.xml · nonDerivative · entry 1 Brady Todd C · CIK 0001579179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,363 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.